Jump to content
World's Largest Herpes Support Group
Sign in to follow this  
otherwiseperky

Breaking Vical News

Recommended Posts

otherwiseperky

Vical's Herpes Simplex Vaccines Protect Against Lethal Challenge and Demonstrate Significant Therapeutic Benefit in Animal Models

PR-Logo-GlobeNewswire.gif

SAN DIEGO, Jul 26, 2010 (GlobeNewswire via COMTEX) -- Vical Incorporated /quotes/comstock/15*!vicl/quotes/nls/vicl (VICL 3.45, +0.17, +5.18%) today announced that its prophylactic Vaxfectin®-formulated plasmid DNA (pDNA) vaccine against herpes simplex virus type 2 (HSV-2) protected mice against lethal challenge, provided sterilizing immunity and inhibited viral counts at both the primary and latent infection sites. The Vaxfectin® adjuvant substantially improved vaccine effectiveness. A related vaccine significantly reduced the recurrence of HSV-2 lesions in a therapeutic model using guinea pigs with latent infection. HSV-2 is a sexually transmitted virus which is the leading cause of genital herpes. Approximately one out of every six individuals in the United States and an estimated one out of every four worldwide is infected by HSV-2 before age 50. HSV-2 infection also significantly increases the risk of acquiring HIV-1.

David Koelle, M.D., professor of medicine in the Division of Allergy and Infectious Diseases at the University of Washington School of Medicine, who led this research, said, "The complete protection and high rate of sterilizing immunity observed in our initial mouse studies are quite impressive with such a safe and practical vaccine platform. We are particularly encouraged by the ability of this novel vaccine to address both primary and latent infection sites."

Initial results presented Saturday at the International Herpes Workshop (Salt Lake City, July 24 -- 30) demonstrated that an appropriate dose of the prophylactic Vaxfectin®-formulated vaccine, which encoded the HSV-2 glycoprotein D (gD2) antigen:

-- Elicited antibody responses in 100% of mice against the encoded antigen; -- Protected 100% of mice against subsequent challenge with a lethal dose of live virus; -- Reduced viral shedding in mice at both the primary and latent infection sites; and -- Elicited sterilizing immunity in 80% of mice as evidenced by no detectable virus after challenge at either the primary (vagina) or latent (dorsal root ganglia) infection sites.A therapeutic version of the vaccine, which encoded the gD2 antigen as well as the tegument proteins UL46/UL47, significantly reduced recurrence of HSV-2 lesions in guinea pigs with latent infection (p<0.05). Three doses of Vaxfectin®-formulated vaccine were administered after resolution of the primary infection.

The preclinical development is being funded under a two-year, $2.0 million Phase II Small Business Technology Transfer (STTR) grant awarded in 2008 by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services. The grant period was recently extended to allow preclinical development to continue for a third year. The $2.0 million Phase II STTR grant supplements the $0.3 million awarded to Vical in 2005 for the HSV-2 vaccine program under a Phase I STTR grant from the NIAID, which partially funded Vical's initial development of the HSV-2 vaccine.

The initial preclinical development activities covered by the $2.0 million grant are being conducted at the University of Washington School of Medicine and the Sealy Center for Vaccine Development, both centers of excellence in herpes virus research. The vaccine is being designed primarily for use in people already infected with HSV-2, with the goal of reducing or eliminating periodic viral flare-ups and the associated viral shedding and transmission.

About HSV-2

HSV-2 is a member of the herpes virus family, and is the leading cause of genital herpes worldwide. In the United States, HSV-2 infects some 1.6 million new people per year, with approximately 500,000 of those suffering from disease symptoms. At least 40 million people in the United States are infected with HSV-2. Even higher infection rates are evident in developing countries, with further complications in people also infected with HIV. All HSV-2 infections are permanent and result in periodic virus shedding.

There is no approved vaccine for HSV-2. Although antiviral regimens have become a standard of care, their inconvenience, cumulative cost and potential for drug resistance further underscore the need for safe, new approaches to reducing HSV-2 lesions, shedding, and transmission. Estimated costs of treating HSV-2 in the United States alone are close to $1 billion, primarily for drugs and outpatient medical care. Additional indirect costs from HSV-2 infection, such as lost work hours, are more than $200 million annually in the United States.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected, including: whether Vical or others will continue development of the HSV-2 vaccine; whether all funding under the grant will be received by the company; whether additional funding will be available to support further development; whether the results from animal testing will be predictive of results in humans; whether the development efforts will result in a vaccine that can generate immune responses sufficient to reduce or eliminate periodic viral flare-ups and the associated viral shedding and transmission; whether the Vaxfectin® adjuvant will effectively enhance the performance of the HSV-2 vaccine; whether Vical or its collaborative partners will seek or gain approval to market the HSV-2 vaccine or any other product candidates; whether Vical or its collaborative partners will succeed in marketing the HSV-2 vaccine or any other product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Share this post


Link to post
Share on other sites
smilesandsunshine

It's comforting to know there are several treatments/cures/vaccines in the works. I'm praying that there will be positive breakthroughs soon!!

Share this post


Link to post
Share on other sites
Coolen

If it works for HSV II... will it work for HSV I?

I like the part that significant latent viral count is pumped down... It's not a mutant virus, it's an inhibitor.

I like the part also that 100% mice responded positively.

And I like the part that... soon, significant latent viral count is pumped down to 0! If this company makes it, at least we have reasons to know we can wait for the cure without complications, and we can wait for at least a few years.

And more, I like the part that implies Prof Bloom could really succeed in his Hammerhead Ribozymes. If this vaccine can be delivered, Hammerhead R shouldn't have a bigger problem.

Toast to a cure soon, people!

Share this post


Link to post
Share on other sites
Panacea

Thanks, more hope that someday soon we'll be able to put this whole experience behind us.

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Sign in to follow this  

  • The Hive is Thriving!

    • Total Topics
      69,917
    • Total Posts
      471,958
  • Posts

    • blurneworder
      Your symptoms and photos match exactly what I've been dealing with on and off since October 2018 after I had a a really bad flu that brought about tingling on my lips. It felt like a cold sore was going to develop, but a bunch of tiny white bumps showed up that doctors have yet to fully explain what it is. I also have a constant feeling of a dry, chapped upper lip. A few weeks later the white tongue showed up. I'm also currently dealing with a change in taste in my mouth. I eventually tested positive fro HSV1 months later, but I don't know where on my body it is. I also have discoloration on my the tip of my penis. One dentist told me I had bacteria covering my tongue, and another dentist said nothing looked suspicious. I also get the cut on my tongue.  Prepare yourself for a journey of doctors telling you that you look normal when, in fact, you do not.
    • WilsoInAus
      @CheekyMunkey there is absolutely no way you, me or anyone has any chance of diagnosing what issues inside the mouth might be. There are simply too many issues that create similar looking outcomes. All I can say is that issues inside the mouth are way, way less likely to be related to herpes compared to if you were having issues on the lips.
    • CheekyMunkey
      Hi mate.  Thank you for responding. I do feel better but I think the oral might be the issue. I was looking at my tongue and it looks white. Well whiter than normal. Also about 3 days ago I had a really sharp pain in my tongue which lasted like seconds. Later in the day when I saw it it had like a line cut into it. Is it a lesion? I have no pain in my tongue at all, no fluid filled sores but I noticed that Its shape isn't right. Like a bits missing on the tip of the right hand side. I've added two pics. It looks whiter in the pics then it actually is but I noticed red dots all down near the tip. Could that be something? Herpes? Also, where the tongue goes out of shape there is nothing on that side. I did burn my mouth on some pizza on the day I felt that sharp pain so not sure if that's got something to do with it.  https://ibb.co/zhphnMD https://ibb.co/G0pPRLh Thanks in advance.
    • RNY18
      Personally, I'm still wondering how likely is it China will cure HSV before the States does ?...
    • WilsoInAus
      I’m sorry your still angry, but drop the relationship with the Jay profiles and you will feel much better about life, I promise.
×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.